Bristol Myers Squibb’s Zeposia (ozanimod) Receives CHMP’s Positive Opinion for Adult Patients with Moderately to Severely Active Ulcerative Colitis Published: 15 Oct, 2021 | Tags: Bristol Myers Squibb, Zeposia, ozanimod, […]readmore
Tags : Sarclisa
Shots: The approval is based on P-III IKEMA study assessing Sarclisa in combination with carfilzomib and dexamethasone (Kd) in 302 patients with relapsed MM who have received 1 to 3 […]readmore
Shots: The approval is based on data from the P-III IKEMA study evaluating Sarclisa + carfilzomib and dexamethasone (Kd) vs Kd alone in 302 patients with relapsed MM across 69 […]readmore
Shots: The NICE has issued FAD which is based on the P-III ICARIA-MM trial assessing isatuximab + pom-dex vs pom-dex in patients prior treated with 3L treatment and at least […]readmore
Shots: EC’s approval is based on P-III ICARIA-MM study assessing Sarclisa + (pomalidomide and dexamethasone) pom-dex vs pom-dex as monothx. for patients with r/r MM, prior treated with at least […]readmore
The US FDA’s Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 48 new products so far in 2019. However, there is […]readmore
Shots: The P-III trial involves assesing of Sarclisa (IV, 10mg/kg qw for four weeks) in combination with carfilzomib (20/56mg/m2, bid) and dexamethasone in 302 patients with relapsed multiple myeloma across […]readmore
Shots: The EMA’s CHMP positive opinion is based on P-III ICARIA-MM study assessing Sarclisa + pom-dex vs pom-dex as monothx. in patients with r/r MM prior treated with two therapies […]readmore
Shots: The approval is based on P-III ICARIA-MM study Sarclisa (IV, 10mg/kg) + pomalidomide + dexamethasone (pom-dex) vs pom-dex as monothx. in patients with RRMM, prior treated with at least […]readmore